next generation of weight-loss drugs could be launched next year, and they could be game-changing. treatment, being dubbed "Ozempic 2.0," is pill version of already widely-used Ozempic. Novo Nordisk, the pharmaceutical company developing new tablet form, said its initial clinical trials revealed that Ozempic 2.0 "lowered weight by average of 10.5 per cent". Rival company Eli Lilly is also working on pill. Its executive vice president, Kenneth Custer, said: "We are moving with urgency toward global regulatory submissions to potentially meet needs of patients." The drugs are currently awaiting approval from Food and Drug Administration (FDA) in USA.
game-changing medicines could make life much easier for those hoping to shed weight, and for people with diabetes. Eli Lilly Chief Scientific Officer Dan Skovronsky said: "For majority of patients, this could be main medicine that they need to control their type 2 diabetes as well as their obesity." Currently, the drug is administered in the form of once-weekly injection via injectable pen. The pen has to be refrigerated. Mr Custer told reporters: "If approved, we are ready to offer convenient, once-daily pill that can be scaled globally, removing barriers and redefining how obesity is treated around world." It is also likely that new treatment will be cheaper.
